The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells
Open accessAbstract
The need for an intact immune system for cancer radiation therapy to be effective suggests that radiation not only acts directly on the tumor but also indirectly, through the activation of host immune components. Recent studies demonstrated that endogenous type I interferons (type I IFNs) play a role in radiation-mediated anti-tumor immunity by enhancing the ability of dendritic cells to cross-prime CD8+ T cells. However, it is still unclear to what extent endogenous type I IFNs contribute to the recruitment and function of CD8+ T cells. Little is also known about the effects of type I IFNs on myeloid cells. In the current study, we demonstrate that type I and type II IFNs (IFN-γ) are both required for the increased production of CXCL10 (IP-10) chemokine by myeloid cells within the tumor after radiation treatment. Radiation-induced intratumoral IP-10 levels in turn correlate with tumor-infiltrating CD8+ T cell numbers. Moreover, type I IFNs promote potent tumor-reactive CD8+ T cells by directly affecting the phenotype, effector molecule production, and enhancing cytolytic activity. Using a unique inducible expression system to increase local levels of IFN-α exogenously, we show here that the capacity of radiation therapy to result in tumor control can be enhanced. Our preclinical approach to study the effects of local increase in IFN-α levels can be used to further optimize the combination therapy strategy in terms of dosing and scheduling, which may lead to better clinical outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 3×
“Irradiation was performed on nonanesthetized mice using a (137)Cs source as previously described [6].”
BackgroundMethodSelf-citationBurnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., Fu, Y.-X., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 878
Inflammatory cytokines as a third signal for T cell activation
Curtsinger, J. M., & Mescher, M. F. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.02.013 · Cited by 615
Yamada, Y., Bilsky, M. H., Lovelock, D. M., Venkatraman, E. S., Toner, S., Johnson, J., Zatcky, J., Zelefsky, M. J., & Fuks, Z. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.046 · Cited by 542
Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity
Lugade, A. A., Sorensen, E. W., Gerber, S. A., Moran, J. P., Frelinger, J. G., & Lord, E. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3132 · Cited by 485
Self-citationA weak signal for strong responses: interferon-alpha/beta revisited
Taniguchi, T., & Takaoka, A. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35073080 · Cited by 483
Kondo, T., Kobayashi, J., Saitoh, T., Maruyama, K., Ishii, K. J., Barber, G. N., Komatsu, K., Akira, S., & Kawai, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222694110 · Cited by 345
Interferon-alpha in tumor immunity and immunotherapy
Belardelli, F., Ferrantini, M., Proietti, E., & Kirkwood, J. M. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00022-3 · Cited by 337
DIMERIZATION AS A REGULATORY MECHANISM IN SIGNAL TRANSDUCTION
Klemm, J. D., Schreiber, S. L., & Crabtree, G. R. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.569 · Cited by 323
Advances in Radiotherapy and Implications for the Next Century: A Historical Perspective
Connell, P. P., & Hellman, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-07-6871 · Cited by 283
Interferon-α and cancer: Mechanisms of action and new perspectives of clinical use
Ferrantini, M., Capone, I., & Belardelli, F. (2007) · Biochimie · doi:10.1016/j.biochi.2007.04.006 · Cited by 268
Interferon-alpha as an immunotherapeutic protein.
Brassard, D., Grace, M. J., & Bordens, R. W. (2002) · PubMed · Cited by 247
Hong, M., Puaux, A.-L., Huang, C., Loumagne, L., Tow, C., Mackay, C., Kato, M., Prévost-Blondel, A., Avril, M.-F., Nardin, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1466 · Cited by 246
Interferon-α as an immunotherapeutic protein
Brassard, D. L., Grace, M. J., & Bordens, R. W. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.4.565 · Cited by 223
INCREASED SURVIVAL IN MICE INOCULATED WITH TUMOR CELLS AND TREATED WITH INTERFERON PREPARATIONS
Gresser, I., Bourali, C., Lévy, J. P., Fontaine-Brouty-Boyé, D., & Thomas, M. T. (1969) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.63.1.51 · Cited by 176
The Tumor-Immune Microenvironment and Response to Radiation Therapy
Shiao, S. L., & Coussens, L. M. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9194-9 · Cited by 138
IFN-γ Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor
Gerber, S. A., Sedlacek, A. L., Cron, K. R., Murphy, S. P., Frelinger, J. G., & Lord, E. M. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.041 · Cited by 131
Self-citation(1998) · PubMed · Cited by 121
Dimerizer-regulated gene expression
Pollock, R. M., & Clackson, T. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00373-7 · Cited by 109
Endogenous type I interferons as a defense against tumors
Gresser, I., & Belardelli, F. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00035-1 · Cited by 105
Rayamajhi, M., Humann, J., Kearney, S. J., Hill, K. K., & Lenz, L. L. (2010) · Virulence · doi:10.4161/viru.1.5.12787 · Cited by 69
Sorensen, E. W., Gerber, S. A., Frelinger, J. G., & Lord, E. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903210 · Cited by 63
Self-citationWong, L. H., Hatzinisiriou, I., Devenish, R. J., & Ralph, S. J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.11.5475 · Cited by 63
Enhanced Tumor Development in Mice Lacking a Functional Type I Interferon Receptor
Picaud, S., Bardot, B., Maeyer, E. D., & Seif, I. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900252952244 · Cited by 60
Wong, L. H., Hatzinisiriou, I., Devenish, R. J., & Ralph, S. J. (1998) · PubMed · Cited by 58
Gerber, S. A., & Pober, J. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.1052 · Cited by 54
Self-citationKline, J. P., Zhang, L., Battaglia, L., Cohen, K. S., & Gajewski, T. F. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100845 · Cited by 49
Gerber, S. A., Sorensen, E. W., Sedlacek, A. L., Lim, J. Y. H., Skrombolas, D., Frelinger, J. G., & Lord, E. M. (2012) · Immunology · doi:10.1111/imm.12037 · Cited by 31
Self-citationThe host immunological response to cancer therapy: An emerging concept in tumor biology
Voloshin, T., Voest, E. E., & Shaked, Y. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.03.007 · Cited by 27
Vogel, R., Mammeri, H., & Mallet, J. J. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.125 · Cited by 13
Cited by
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Radiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H., Deng, L., & Fu, Y.-X. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,070
Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
Chemokines and the immune response to cancer
Ozga, A. J., Chow, M. T., & Luster, A. D. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.012 · Cited by 830
Metadata
- Authors
- Lim, J. Y. H., Gerber, S. A., Murphy, S. P., & Lord, E. M.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2013-12-20
- Volume
- 63
- Issue
- 3
- Pages
- 259-271
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W1984054147
- Cited by
- 257
- References
- 33
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.